title: Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B.
authors.forename: K R
authors.initials: KR
authors.lastname: Rai
authors.forename: J
authors.initials: J
authors.lastname: Cuttner
authors.forename: J F
authors.initials: JF
authors.lastname: Holland
authors.forename: R
authors.initials: R
authors.lastname: Davis
authors.forename: R
authors.initials: R
authors.lastname: Mayer
authors.forename: O R
authors.initials: OR
authors.lastname: McIntyre
authors.forename: H
authors.initials: H
authors.lastname: Preisler
authors.forename: J
authors.initials: J
authors.lastname: Yates
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004338:Drug Combinations / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D013420:Sulfamethoxazole / Q000008:administration & dosage; D013997:Time Factors; D014295:Trimethoprim / Q000008:administration & dosage; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014481:United States
chemical_list: D004338:Drug Combinations; D003561:Cytarabine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D003630:Daunorubicin